Literature DB >> 27788931

Frequency of Cardiac Death and Stent Thrombosis in Patients With Chronic Obstructive Pulmonary Disease Undergoing Percutaneous Coronary Intervention (from the BASKET-PROVE I and II Trials).

Tannas Jatene1, Tor Biering-Sørensen2, Kotaro Nochioka3, Fernanda Marinho Mangione4, Kim Wadt Hansen5, Rikke Sørensen2, Jan Skov Jensen2, Peter Godsk Jørgensen2, Raban Jeger6, Christoph Kaiser6, Matthias Pfisterer6, Søren Galatius5.   

Abstract

Chronic obstructive pulmonary disease (COPD) is associated with long-term all-cause death after percutaneous coronary intervention with bare-metal stents. Regarding other outcomes, previous studies have shown conflicting results and the impact of drug-eluting stent (DES) in this population is not well known. We analyzed 4,605 patients who underwent percutaneous coronary intervention with bare-metal stents (33.1%) or DES (66.9%) from the Basel Stent Kosten-Effektivitats Trial-Prospective Validation Examination trials I and II. COPD patients (n = 283, 6.1%), were older and had more frequently a smoking or cardiovascular event history. At 2-year follow-up, cumulative event rates for patients with versus without COPD were the following: major adverse cardiac events (MACE: composite of cardiac death, nonfatal myocardial infarction, and target vessel revascularization): 15.2% versus 8.1% (p <0.001); all-cause death: 11.7% versus 2.4% (p <0.001); cardiac death: 5.7% versus 1.2% (p <0.001); myocardial infarction: 3.5% versus 1.9% (p = 0.045); definite/probable/possible stent thrombosis: 2.5% versus 0.9% (p = 0.01); and major bleeding: 4.2% versus 2.1% (p = 0.014). After adjusting for confounders including smoking status, COPD remained an independent predictor for MACE (hazard ratio [HR] 1.80, 95% confidence interval [CI] 1.31 to 2.49), all-cause death (HR 3.62, 95% CI 2.41 to 5.45), cardiac death (HR 3.12, 95% CI 1.74 to 5.60), and stent thrombosis (HR 2.39, 95% CI 1.03 to 5.54). We did not find evidence of an interaction between COPD and DES implantation (p for interaction = 0.29) for MACE. In conclusion, COPD is associated with increased 2-year rates of all-cause death, cardiac death, and stent thrombosis after stent implantation. DES use appears to be beneficial also in patients with COPD.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27788931     DOI: 10.1016/j.amjcard.2016.09.013

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  The bidirectional relationship between chronic obstructive pulmonary disease and coronary artery disease.

Authors:  Ayham Daher; Michael Dreher
Journal:  Herz       Date:  2020-04       Impact factor: 1.443

2.  Long-Term Outcomes for Chinese COPD Patients After PCI: A Propensity Score Matched, Double-Cohort Study.

Authors:  Yitian Zheng; Yu Qi; Samuel Seery; Wenyao Wang; Wei Zhao; Tao Shen; Lequn Zhou; Jie Yang; Chen Li; Xuliang Wang; Jun Gao; Xiangbin Meng; Erdan Dong; Yi-Da Tang
Journal:  Front Cardiovasc Med       Date:  2022-06-09

Review 3.  Major adverse cardiac events and mortality in chronic obstructive pulmonary disease following percutaneous coronary intervention: a systematic review and meta-analysis.

Authors:  Pravesh Kumar Bundhun; Chakshu Gupta; Guang Ma Xu
Journal:  BMC Cardiovasc Disord       Date:  2017-07-17       Impact factor: 2.298

4.  The association between recent hospitalized COPD exacerbations and adverse outcomes after percutaneous coronary intervention: a nationwide cohort study.

Authors:  Wei-Chieh Lin; Chang-Wen Chen; Chin-Li Lu; Wu-Wei Lai; Min-Hsin Huang; Liang-Miin Tsai; Chung-Yi Li; Chao-Han Lai
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-01-03

5.  Effects of COPD on Left Ventricular and Left Atrial Deformation in Patients with Acute Myocardial Infarction: Strain Analysis Using Speckle-Tracking Echocardiography.

Authors:  Julian Grebe; Tobias Müller; Ertunc Altiok; Michael Becker; András P Keszei; Nikolaus Marx; Michael Dreher; Ayham Daher
Journal:  J Clin Med       Date:  2022-03-30       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.